Eli Lilly Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly

LLY 993.35

+1.1%

Dec 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (151)	4/20/1998 8:06:00 AM
From: Henry Niman	of 642

Tom Burton from WSJ was just on CNBC. Most of the info is a re-run for readers of this board but here's a synopsis: LLY has two sets of data over a 2 1/2 year period. In one study Evista produced a 74% reduction in the incidence of breast cancer (n=7,000) and in another study the reduction was 58% (n=12,000). In addition, unlike Tamoxifen, there was no increase in the incidence of uterine cancer. Side effects were mentioned and like Tamoxifen it causes an increased incidence of blood clots. Of most import to Ligand long term shareholders were the comments on PREVENTION. Although the ultimate success of Evista is unknown, it is clearly a forerunner for a new class of drugs called designer estrogens (SERMs) in which drug makers try to optimize effects in the bone and cardiovascular areas and minimize side effects related to uterine and breast tissue proliferation. As most readers of this board know, LGND has SERM programs with LLY (Evista), PFE (Droloxifene and CP-366,156), and AHP (TSE424). Moreover, it has its own designer androgen program (LGD1331), which is ready to enter the clinic (see home.att.net ).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next